Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Pharma
Pharma
COPD nod could be worth $3.5B for Dupixent: analyst
Analysts at Evercore ISI believe a label expansion for Sanofi and Regeneron’s Dupixent in COPD would add $3.5 billion in global peak sales.
Kevin Dunleavy
Mar 24, 2023 1:25pm
Judge OKs plaintiff's expert in high-stakes Zantac trial
Mar 24, 2023 11:09am
Brii Biosciences halts manufacture of COVID-19 antibody combo
Mar 24, 2023 11:05am
FDA rejects Incyte's Jakafi XR, hurting pipeline hopes: analyst
Mar 24, 2023 11:05am
Gilead handed its CEO Daniel O'Day a healthy pay bump in 2022
Mar 24, 2023 9:55am
Takeda, Biohaven, Astellas—Fierce Pharma Asia
Mar 24, 2023 8:45am
